Singapore Scouts New Targeted Cancer Treatment Therapies

Cancer happens to be a leading cause of global death and accounts for almost one in six fatalities, with metastatic cancers contributing more than 90% of the overall cancer-related deaths. Apparently, metastatic cancers take place when the cancer cells break away from their original tumour cells in the body, traverse across the blood vessels or the lymph system, and attach themselves to tissues or organs.

This process of cancer cells creating the ability to invade other body parts has surely been a point of interest for numerous scientists so as to explore probable checkpoints when it comes to cancer therapies.

The Mechanobiology Institute, which happens to be at the National Institute of Singapore, has had a team of researchers along with the Department of Biological Sciences under the umbrella of the NUS Faculty of Science and even external collaborators working together to get a deeper appreciation for the cellular activities that are involved in making sure the cancer cells change and pass through the blood vessels.

As per their study, the team has gone on to explore how an essential protein like BPGAP1 happens to be working with cancer cells to bring together another 2 proteins, RhoA and GTPases Rac1, so as to enable the structural changes across the cancer cells for them to move from their original site and thereafter attach themselves to another organ or tissue.

According to the researchers, they can make use of BPGAP1 as both a marker for cancer prognosis as well as a cancer intervention target across varied blood types. They added that with the current breakthrough that they have had, they can inspire novel approaches pertaining to therapeutic design that are related to metastasis and cancer.